Viewing Study NCT01613118

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:58 AM
Ignite Modification Date: 2026-06-26 @ 5:11 AM
Study NCT ID: NCT01613118
Status: COMPLETED
Last Update Posted: 2025-05-15
First Post: 2012-06-04
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Sponsor: Travere Therapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Focal Segmental Glomerulosclerosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Primary FSGS View
None Nephrotic syndrome View
None Steroid Resistant View